{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:31:47Z","timestamp":1787949107114,"version":"build-2784847793"},"reference-count":18,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Czech Republic\u2013conceptual development of research organization","award":["FNOs\/2024 (MH CZ\u2014DRO-FNOs\/2024)"],"award-info":[{"award-number":["FNOs\/2024 (MH CZ\u2014DRO-FNOs\/2024)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Statin intolerance is a serious therapeutic dilemma in secondary cardiovascular prevention (e.g., ESC\/EAS Guidelines 2023). This is especially true when confirmed by genetic predisposition and complicated by rhabdomyolysis. Although several non-statin agents have become available in recent years, evidence regarding their combined use in high-risk statin-intolerant patients remains limited. Furthermore, the pharmacokinetics of statins in toxic concentrations are poorly characterized in clinical settings. Case Presentation: We present two cases of genetically confirmed statin-induced rhabdomyolysis, both accompanied by severe acute kidney injury requiring renal replacement therapy. In both patients, serial measurements of rosuvastatin plasma concentrations revealed markedly delayed elimination, with detectable levels persisting for several weeks despite ongoing dialysis. Estimated half-lives exceeded 7 days in both cases, far beyond the known therapeutic range. Genetic testing identified SLCO1B1, ABCB1, and CYP2C9 polymorphisms linked to reduced hepatic uptake and impaired drug clearance. Following biochemical recovery, both patients were initiated on a triple non-statin lipid-lowering regimen consisting of ezetimibe, bempedoic acid, and inclisiran. The combination was well tolerated, with no recurrence of muscle-related symptoms or biochemical toxicity. LDL-C levels were reduced from 3.05 to 1.59 mmol\/L and from 4.99 to 1.52 mmol\/L, respectively, with sustained response over 12 and 40 weeks. Full lipid profiles demonstrated favorable changes across all parameters. Conclusions: These two cases suggest that the combination of ezetimibe, inclisiran, and bempedoic acid may serve as a safe and effective therapeutic option in patients with severe statin intolerance. Pharmacogenetic testing and serial pharmacokinetic assessment may guide personalized lipid-lowering strategies and improve outcomes in this challenging patient population.<\/jats:p>","DOI":"10.3390\/ph18060818","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:47:34Z","timestamp":1748512054000},"page":"818","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3537-0342","authenticated-orcid":false,"given":"Jozef","family":"Dodul\u00edk","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Cardiology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Pl\u00e1\u0161ek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-754X","authenticated-orcid":false,"given":"Ivana","family":"Kac\u00ed\u0159ov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"U\u0159inovsk\u00e1","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8700-2395","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Vrtal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"V\u00e1clav\u00edk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: Mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2024.03.006","article-title":"Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid","volume":"84","author":"Yarrarapu","year":"2024","journal-title":"J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group, 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"95C","DOI":"10.1016\/j.amjcard.2005.12.016","article-title":"Benefit versus risk in statin treatment","volume":"97","author":"Guyton","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_5","first-page":"e46069","article-title":"Rhabdomyolysis in a Long-Term Statin User Without Traditional Risk Factors: A Case Report","volume":"15","author":"Naritaka","year":"2023","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Burnett, H., Cichewicz, A., Natani, H., Bhowmik, D., Buesch, K., Fahrbach, K., Reichelt, A., Neupane, B., Pierre, V., and Jindal, R. (J Cardiovasc. Pharmacol., 2025). Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis, J Cardiovasc. Pharmacol., ahead of print.","DOI":"10.1097\/FJC.0000000000001712"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"SEARCH Collaborative Group, Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., and Collins, R. (2008). SLCO1B1 variants and statin-induced myopathy\u2014A genomewide study. N. Engl. J. Med., 359, 789\u2013799.","DOI":"10.1056\/NEJMoa0801936"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1093\/eurheartj\/suab090","article-title":"New players in the treatment of hypercholesterolaemia: Focus on bempedoic acid and inclisiran","volume":"23","author":"Ruscica","year":"2021","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5414\/CP204536","article-title":"Degree of serum LDL cholesterol reduction by simvastatin and ezetimibe is dependent on baseline LDL cholesterol concentration but not on baseline values and changes in cholesterol synthesis and absorption parameters","volume":"62","author":"Stellaard","year":"2024","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ecl.2022.01.004","article-title":"Safety of Statins and Nonstatins for Treatment of Dyslipidemia","volume":"51","author":"Newman","year":"2022","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/6\/818\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:09Z","timestamp":1760031789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/6\/818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ph18060818"],"URL":"https:\/\/doi.org\/10.3390\/ph18060818","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}